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Abstract
BACKGROUND
Mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN) is a rare
diagnosis, mainly encountered in the gastro-entero-pancreatic tract. There is
limited knowledge of its epidemiology, prognosis and biology, and the best
management for affected patients is still to be defined.
AIM
To investigate clinical-pathological characteristics, treatment modalities and
survival outcomes of a retrospective cohort of patients with a diagnosis of
MiNEN.
METHODS
Consecutive patients with a histologically proven diagnosis of MiNEN were
identified at 5 European centres. Patient data were retrospectively collected from
medical records. Pathological samples were reviewed to ascertain compliance
with the 2017 World Health Organisation definition of MiNEN. Tumour
responses to systemic treatment were assessed according to the Response
Evaluation Criteria in Solid Tumours 1.1. Kaplan-Meier analysis was applied to
estimate survival outcomes. Associations between clinical-pathological
characteristics and survival outcomes were explored using Log-rank test for
equality of survivors functions (univariate) and Cox-regression analysis
(multivariable).
RESULTS
Sixty-nine consecutive patients identified; Median age at diagnosis: 64 years.
Males: 63.8%. Localised disease (curable): 53.6%. Commonest sites of origin:
colon-rectum (43.5%) and oesophagus/oesophagogastric junction (15.9%). The
neuroendocrine component was; predominant in 58.6%, poorly differentiated in
86.3%, and large cell in 81.25%, of cases analysed. Most distant metastases
analysed (73.4%) were occupied only by a poorly differentiated neuroendocrine
component. Ninety-four percent of patients with localised disease underwent
curative surgery; 53% also received perioperative treatment, most often in line
with protocols for adenocarcinomas from the same sites of origin. Chemotherapy
was offered to most patients (68.1%) with advanced disease, and followed
protocols for pure neuroendocrine carcinomas or adenocarcinomas in equal
proportion. In localised cases, median recurrence free survival (RFS); 14.0 months
(95%CI: 9.2-24.4), and median overall survival (OS): 28.6 months (95%CI: 18.3-
41.1). On univariate analysis, receipt of perioperative treatment (vs surgery alone)
did not improve RFS (P = 0.375), or OS (P = 0.240). In advanced cases, median
progression free survival (PFS); 5.6 months (95%CI: 4.4-7.4), and median OS; 9.0
months (95%CI: 5.2-13.4). On univariate analysis, receipt of palliative active
treatment (vs best supportive care) prolonged PFS and OS (both, P < 0.001).
CONCLUSION
MiNEN is most commonly driven by a poorly differentiated neuroendocrine
component, and has poor prognosis. Advances in its biological understanding are
needed to identify effective treatments and improve patient outcomes.
Key words: Mixed neuroendocrine non-neuroendocrine neoplasm; 2017 World Health
Organisation classification; Mixed adeno-neuroendocrine carcinoma; Gastro-entero-
pancreatic tract; Digestive system; Neuroendocrine neoplasms; Survival outcomes
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN) is a rare, albeit
aggressive diagnosis. Evidence from literature is limited and inconsistent. This study
reports on one of the largest cohorts of patients with a diagnosis of MiNEN in the current
literature, and aims to provide useful suggestions for clinical management, in the absence
of data from clinical trials. Potentially curable cases are most commonly offered surgery
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alone or in combination with chemotherapy or chemo-radiotherapy (predominantly
according to the “standard of care” for adenocarcinomas). Advanced cases are most
often treated with palliative chemotherapy and protocols follow either the “standard of
care” for adenocarcinomas or neuroendocrine carcinomas.
Citation: Frizziero M, Wang X, Chakrabarty B, Childs A, Luong TV, Walter T, Khan MS,
Morgan M, Christian A, Elshafie M, Shah T, Minicozzi A, Mansoor W, Meyer T, Lamarca A,
Hubner RA, Valle JW, McNamara MG. Retrospective study on mixed neuroendocrine non-
neuroendocrine neoplasms from five European centres. World J Gastroenterol 2019; 25(39):
5991-6005
URL: https://www.wjgnet.com/1007-9327/full/v25/i39/5991.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i39.5991
INTRODUCTION
Mixed tumours exhibiting both exocrine and neuroendocrine morphological features
are frequently encountered by pathologists in routine practice, and can originate in all
organs.  Over the years,  these tumours have been assigned variable designations,
giving rise to huge inconsistency within the literature[1]. Since 2000, tumours from the
gastro-entero-pancreatic (GEP) tract consisting of an exocrine and a neuroendocrine
component, accounting for at least a third or 30% of the tumour mass, have been
classified by the World Health Organisation (WHO) as separate entities from their
pure counterparts[2-5].  In 2010, the WHO classification of tumours of the digestive
system[4]  named those  mixed tumours  mixed adeno-neuroendocrine  carcinomas
(MANECs).
MANEC is a rare and controversial diagnosis; data from the current literature are
limited, almost exclusively derived from case reports and small retrospective series,
and inconsistent, mainly due to differences across studies in patient inclusion criteria
(e.g., disease stage, grade of differentiation of the two components, sites of origin),
population size and interpretation of the 2010 WHO definition of MANEC. In fact,
there is still  large disagreement among authors on whether to include goblet cell
carcinoids/carcinomas  of  the  appendix[6]  under  the  diagnosis  of  MANEC,  and
whether  to  consider  mixed  tumours  composed  by  an  adenoma  and  a  well
differentiated  neuroendocrine  component  separately  from MANECs with  more
aggressive  histological  features[7].  The  median  overall  survival  (OS)  of  affected
patients  varies  greatly  across  the  retrospective  series,  ranging between 10  to  78
months (any disease stage or disease stage not specified)[8-13].
The  European  Neuroendocrine  Tumour  Society  (ENETS)  clinical  practice
guidelines recommend that the management of MANEC should follow the standard
of  care  for  pure,  grade  3,  neuroendocrine  carcinoma  (NEC) [ 1 4 ],  since  the
neuroendocrine component in MANEC is most commonly poorly differentiated and
predominant, both in the primary tumours and in distant metastatic sites[15]. However,
other authors suggest treating MANEC according to the clinical practice guidelines
for adenocarcinomas (ADCs) from the same site of origin, when the ADC component
is prevalent and/or the least differentiated[7].
In  2017,  the  WHO classification of  tumours  of  endocrine organs has  renamed
MANECs from the pancreas “mixed neuroendocrine non-neuroendocrine neoplasms”
(MiNENs)[5], in order to better convey the variety of possible combinations between
neuroendocrine and non-neuroendocrine histologies, extending the spectrum of the
latter to incorporate “non-gland-forming” variants (e.g., squamous cell carcinoma or
sarcoma) and precancerous lesions (e.g., adenoma). The term MiNEN currently only
appears in the nomenclature for endocrine neoplasms arising from the pancreas.
However, pathologists commonly extend the use of the phrase and apply it to mixed
tumours meeting the diagnostic criteria and originating from any organ site[16].
It is worth noting that, since the diagnosis of MiNEN is based on a quantitative
threshold,  tissue  biopsies  may  not  be  able  to  accurately  discriminate  between
MiNENs  and  neuroendocrine  neoplasms  with  a  minor  non-neuroendocrine
differentiation (< 30%), or vice versa, potentially accounting for underestimation of
the frequency of this diagnosis. As a result of the limitations of diagnostic methods, as
well as the paucity and inconsistency of available evidence, the actual epidemiology
and prognosis of MiNEN remains unknown.
Furthermore, identifying effective therapeutic strategies for MiNEN represents a
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major  challenge,  which can be  mainly  explained by;  (1)  the  lack of  high-quality
evidence from large prospective trials, due to the rareness and limited awareness of
this diagnosis outside the community of clinicians and researchers with interest in
neuroendocrine neoplasms; and (2) the different sensitivity of the two histologies to
conventional systemic treatments and radiotherapy; the selective treatment of one of
the two components can favour the clonal expansion of the other, leading to the rapid
development of resistance.
The present study aimed to collect data from a large, retrospective, multi-centre,
series of patients with a diagnosis of MiNEN, for whom there was compliance with
the  2017  WHO  classification [5],  confirmed  by  pathologists  with  expertise  in
neuroendocrine  neoplasms,  to  inform  clinicians  on  the  clinical-pathological
characteristics,  biological  behaviour and management of  this  poorly understood
disease.
MATERIALS AND METHODS
Patient and tumour samples
Consecutive  patients  with  a  diagnosis  of  MiNEN,  as  per  the  2017  WHO
classification[5],  were retrospectively identified from 5 European Institutions, 4 of
which are ENETS Centres of Excellence; The Christie National Health Service (NHS)
Foundation Trust in Manchester (United Kingdom), The Royal Free London NHS
Foundation Trust in London (United Kingdom), University Hospitals Birmingham
NHS Foundation Trust (United Kingdom), Edouard Herriot Hospital (Hospices Civils
de Lyon) (France), and Cardiff and Vale University Health Board (United Kingdom).
All pathological samples, obtained by either surgical resection or tissue biopsy from
primary tumours or metastatic sites, were reviewed by pathologists with expertise in
neuroendocrine  neoplasms,  and  fulfilled  the  2017  WHO  diagnostic  criteria  for
MiNEN (each component accounting for at least 30% of the tumour mass)[5]. Only
patients with a primary tumour from the GEP tract, or of unknown origin, where
other primary sites were excluded, were considered eligible for inclusion in this
study.  Diagnosis  by  cytology  (e.g.,  brushing  or  fine  needle  aspiration)  was  not
permitted,  as  deemed not  informative enough to allow an accurate  diagnosis  of
MiNEN. Other exclusion criteria included; goblet cell carcinoids Tang subtype A,
ADC ex-goblet cell carcinoids Tang subtype B and C[6], and amphicrine tumours. In
fact, studies reporting on goblet cell carcinoids (any Tang subtype) indicate that these
tumours rarely exhibit a neuroendocrine component exceeding 30% of the tumour
mass[7,17],  and  seem  to  have  a  more  favourable  prognosis  than  patients  with
MiNENs[11,12].
Demographic characteristics, treatment modalities and clinical outcomes of eligible
patients, and morphological data of corresponding tumour samples were collected
from local medical records (approved by local audit committees). This study was
approved by the Christie NHS Foundation Trust Audit committee (16/1806).
Due to differences in staging systems among tumours from different sites of origin,
the  disease  stage  was  classified  as  follows;  localised  (Loc),  if  the  tumour  was
amenable to curative treatment, whether or not loco-regional nodes were affected,
and in the absence of distant metastases;  advanced (Adv), if  the tumour was not
amenable to curative treatment, either because locally infiltrative or because of the
presence of distant metastases.
Chemotherapy and chemo-radiotherapy regimens, used either in the Loc or Adv
setting, were defined as “ADC-like” or “NEC-like” according to whether they were in
keeping with the “standard-of-care” for the treatment of ADCs from the same site of
origin or NECs, respectively.
The following endpoints were used to investigate patient and treatment outcomes;
recurrence-free-survival (RFS) (defined as the time from the beginning of the initial
curative treatment to radiological or clinical evidence of recurrence of the tumour or
tumour-related death), progression-free-survival (PFS) (defined as the time from the
diagnosis  of  Adv  disease  or  the  beginning  of  active  palliative  treatment  to
radiological/clinical evidence of progression of the tumour or death from any cause),
and OS (defined as the time from the initial pathological diagnosis to death from any
cause). For patients with Loc MiNEN who developed recurrent Adv disease, PFS and
OS were also calculated from the time of radiological diagnosis of Adv disease or the
beginning of active palliative treatment to the time of radiological/clinical evidence of
further progression or death from any cause; these PFS and OS data were combined
with those from patients with Adv disease “ab initio”, in order to increase the sample
size of the Adv subgroup.
The date of data cut-off was the 28th  of February 2018. The follow-up time was
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estimated from the date of the first contact by the patient with the institution and the
date of last follow-up visit,  or contact,  or death from any cause.  The response to
chemotherapy  or  chemo-radiotherapy  was  assessed  according  to  the  Response
Evaluation Criteria In Solid Tumors (RECIST) version 1.1[18]. Frequency of imaging
was performed as per institutional and ENETS guidelines[14] (every 3 months).
Statistical analysis
Microsoft excel was used for descriptive statistics, and “R” software was used for
inferential statistics. Survival outcomes (median RFS, PFS and OS) were estimated by
using Kaplan-Meier analysis (patients lost to follow-up were censored at the time of
last  follow-up  visit  or  contact).  Associations  between  clinical  and  pathological
characteristics and survival outcomes were investigated by applying Log-rank test for
equality  of  survivors  function  (univariate),  and  Cox-regression  analysis
(multivariable). Probability values (P) were considered to be statistically significant at
a level < 0.05.
RESULTS
Clinical characteristics of patients and pathological data of tumour samples
A total of 69 consecutive patients with a diagnosis of MiNEN (2017 WHO definition)[5]
were eligible for inclusion in the study. The date of diagnosis ranged from the 1st of
September  1980 to  the  1st  of  August  2017.  The median follow-up time was 11.5
months  [95%  confidence  interval  (CI);  6.5-13.5].  Baseline  demographic  and
clinical/pathological  characterist ics  are  summarised  in  Table  1  and
Supplemental Table 1. The median age of patients at diagnosis was 64 years (range:
34-89).
Pathological material  for diagnosis (collection procedure;  surgery 58%, biopsy
36.2%, unknown but not fine needle aspiration or brushings in 5.8%) was obtained
from primary tumours in 50 cases (72.5%) and metastatic  sites  in 5  cases (7.2%),
whereas the site from where the tumour tissue was retrieved could not be ascertained
in 14 cases (20.3%). The neuroendocrine component was predominant and poorly
differentiated, grade 3, in 58.7% and 86.4% of cases for which this information was
available, respectively. The median Ki-67 index of the neuroendocrine component
(recorded for 56 patients) was 70% (range: 2%-95%). The predominant histology in
MiNEN, and the morphological subtype of the neuroendocrine component was not
available  from  pathological  reports  in  33.3%  and  72.4%  of  cases,  respectively.
Immunohistochemical data on diagnostic samples of MiNEN are presented in Table 2.
Additional pathological material from synchronous or metachronous metastatic
sites was available for 15 patients and consisted of a pure NEC in 11 (73.4%) cases, a
pure ADC in 1 (6.6%), and an admixture of both histologies in 3 (20%).
Management and clinical outcomes of patients
Treatment modalities of MiNEN was available for 36 patients with Loc disease and 54
patients with Adv disease, and are illustrated in Figure 1. The Adv subgroup included
both patients who presented with Adv disease at diagnosis (n = 29) and patients who
developed recurrent metastatic disease after initial curative treatment (n = 25).
Chemotherapy and chemo-radiotherapy regimens administered with curative
intent in the Loc setting followed ADC-like protocols in 13/18 (72.2%) cases and NEC-
like protocols in 2/18 (11.1%) cases [for 3/18 (16.7%) patients, the chemotherapy
regimen used was unknown]. Regimens of systemic treatment administered with
palliative intent in the Adv setting were in keeping with ADC-like protocols in 17/37
(45.9%) cases and NEC-like protocols in 17/37 (45.9%) cases [for 3/37 (8.1%) patients,
the chemotherapy regimen used was unknown]. Descriptive associations between the
predominant and/or most aggressive component in diagnostic samples, or second
biopsies  obtained  at  the  time  of  diagnosis  of  Adv  disease  (pre-treatment),  and
chemotherapy or chemo-radiotherapy regimens used were possible for 30 patients
(Supplemental Table 2); the choice of regimen (either NEC-like or ADC-like) was in
line with the predominant or most aggressive component in 20 (67%) cases.
In the Adv setting, the response to first-line chemotherapy or chemo-radiotherapy
was assessed for 30 patients; 2 (6.7%) had complete response, 4 (13.3%) had partial
response, 13 (43.3%) had stable disease (disease control rate; 63.3%), and 11 (36.6%)
had  progressive  disease.  Correlations  between  treatment  response  and
predominant/most  aggressive  histology  or  chemotherapy/chemo-radiotherapy
protocols used were not interrogated, as individual subgroups were too small to
allow reliable statistical analyses.
Eleven  patients  received  second-line  active  treatment;  9  chemotherapy  (5-
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Table 1  Demographic and clinical-pathological characteristics in patients with a diagnosis of mixed neuroendocrine non-neuroendocrine
neoplasm
Variable Category n (%) Variable Category n (%)
Gender Predominant component
Female 25 (36.2) NE 27 (39.1)
Male 44 (63.8) Non-NE 12 (17.4)
Equal proportion 7 (10.1)
NA 23 (33.3)
Disease stage Morphology of NE component
Localised 37 (53.6) Large cell 13 (18.8)
Advanced 30 (43.5) Small cell 5 (7.2)
NA 2 (2.9) Others 1 (1.4)
NA 50 (72.4)
Primary tumour site Grading of NE component
Colon 22 (31.9) Grade 1 3 (4.3)
Oesophagus/OGJ 11 (15.9) Grade 2 14 (20.3)
Rectum 8 (11.6) Grade 3 57 (82.6)
Small bowel/ICJ 8 (11.6) NA 3 (4.3)
Pancreas 6 (8.7)
Stomach 4 (5.8) Ki-67 of NE component
Anus 4 (5.8) Median 70% (55-68)
Biliary tract 3 (4.3%) < 55% 19 (27.5)
Appendix 2 (1.9) ≥ 55% 37 (53.6)
Unknown 1 (1.5) NA 13 (18.8)
Histology of non-NE component
Lower GI 44 (63.8) ADC 51 (39.1)
Upper GI 15 (21.7) Adenoma 2 (17.4)
PB 9 (13) Carcinoma/SCC 1 (10.1)
Unknown 1 (1.5) NA 15 (33.3)
Grading of non- NE component
Grade 1 10 (14.5)
Grade 2 14 (20.3)
Grade 3 20 (29.0)
Adenoma 2 (17.4)
NA 23 (33.3)
Note: the sum of the percentages might not reach 100% due to rounding. ECOG: Eastern Cooperative Oncology Group; PS: Performance status; Loc:
Localised stage; Adv: Advanced stage; NE: Neuroendocrine; ADC: Adenocarcinoma; SCC: Squamous cell carcinoma; OE: Oesophageal; OGJ: Oesophago-
gastric junction; ICJ: Ileo-caecal junction; Lower GI: Lower gastrointestinal tract; Upper GI: Upper gastrointestinal tract; PB: Pancreatico-biliary tract; NA:
Not available.
fluorouracil-based  in  6,  gemcitabine-based  in  1,  cisplatin/etoposide  in  1,
cyclophosphamide/adriamycin/vincristine in 1), 1 chemo-radiotherapy and 1 de-
bulking surgery with intraperitoneal chemotherapy.
At the time of data cut-off, the median OS in the whole population (calculated for
63 patients; whether or not death had occurred was unknown in 6 patients) was 15.9
months (95%CI: 12.4-29.6). In the Loc subgroup, 25 (66.7%) patients relapsed and the
median RFS (calculated for 33 patients; whether or not disease relapse occurred was
unknown for 4 patients) was 14.0 months (95%CI: 9.2-24.34), and 22 (64.7%) died. The
median OS was 28.6 months (95%CI: 18.3-41.1) (calculated for 34 patients; whether or
not death occurred was unknown for 3 patients) (Figure 2). Univariate analyses for
RFS and OS in the Loc setting are presented in Table 3. The primary tumour site
(lower gastro-intestinal, upper gastro-intestinal or pancreatico-biliary) significantly
impacted on OS (P < 0.001), with MiNENs of pancreatico-biliary origin seeming to
have the worst outcomes. An age at diagnosis below 70 years (vs ≥ 70) was a positive
prognostic factor for both RFS (P  = 0.023) and OS (P  = 0.017). Female gender was
prognostic for worse OS (P = 0.037) and was associated with a trend towards worse
RFS, although not statistically significant (P = 0.081). The absence of local-regional
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Table 2  Immunohistochemical data on diagnostic samples of mixed neuroendocrine non-
neuroendocrine neoplasm
Variable Category Number %
Synaptophysin
Positive 60 87.0
Negative 0 0
NA 9 13.0
Chromogranin A
Positive 37 53.6
Negative 16 23.2
NA 16 23.2
CD56
Positive 26 37.7
Negative 10 14.5
NA 33 47.8
CK-20
Positive 22 31.9
Negative 11 15.9
NA 36 52.2
CK-7
Positive 24 34.7
Negative 10 14.5
NA 35 50.8
CDX-2
Positive 33 47.8
Negative 4 5.8
NA 32 46.4
Note: The sum of the percentages may not reach 100% due to rounding. NA: Not available.
lymph node metastases in post-operative specimens was prognostic for longer RFS (P
=  0.015),  and  was  associated  with  a  trend  towards  improved  OS,  although  not
statistically significant (P = 0.069). Interestingly, neither the predominant component
nor the receipt of perioperative treatment (vs surgery alone) impacted on PFS or OS.
Multivariable analysis was considered but due to lack of complete data, the number of
analysable  cases  for  each  subgroup  was  too  small  (n  =  1-11)  to  enable  reliable
comparisons.
In the Adv subgroup (survival outcomes calculated for 54 patients; whether or not
disease progression or death occurred was unknown for 1 patient), 48 (88.9%) patients
had progressed and 43 (79.6%) had died, and the median PFS and OS were 5.6 months
(95%CI: 4.4-7.4) and 9.0 months (95%CI: 5.2-13.4), respectively (Figure 2). Univariate
analyses for PFS and OS in the Adv setting are presented in Table 4. The primary
tumour site (lower gastro-intestinal, upper gastro-intestinal or pancreatico-biliary)
significantly impacted on both PFS (P = 0.008) and OS (P < 0.001), with MiNENs of
pancreatico-biliary origin seeming to have the worst outcomes. The receipt of first-line
active treatment (vs  best supportive care alone) was associated with significantly
better PFS (P < 0.001) and OS (P < 0.001), whereas the predominant component did
not  impact  on  ei ther  survival  outcomes.  On  mult ivariable  analysis
(Supplemental Table 3, the primary tumour site retained prognostic significance for
OS (P = 0.016), and had “borderline” prognostic significance for PFS (P = 0.057). In
contrast, the administration of first line active treatment lost significance for both PFS
(P = 0.237) and OS (P = 0.523).
Univariate analysis for RFS, PFS and OS according to immunohistochemical data
from tumour samples at diagnosis was also performed, and significant results can be
summarised as follows; in the Loc setting, CK-7 positive staining was associated with
shorter  RFS  (P  =  0.021)  and  OS  (P  =  0.035),  and  CDX-2  positive  staining  was
associated  with  improved  OS  (P  =  0.009).  In  the  Adv  setting,  Chromogranin  A
positive staining was associated with shorter PFS (P = 0.039).
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Figure 1
Figure 1  Treatment modalities of patients with a diagnosis of mixed neuroendocrine non-neuroendocrine neoplasm according to disease stage.
DISCUSSION
This current study is one of the largest reporting on a population of patients with a
diagnosis of MiNEN in the literature, with expert pathological review confirming the
diagnosis.  The  results  of  this  study  indicate  that,  most  commonly,  MiNEN  is
diagnosed in men and arises from the colon-rectum or oesophagus/oesophago-gastric
junction. These data closely mirror those from a German, single-centre, retrospective
study by Apostolidis et al[19] which included 58 patients with a diagnosis of MiNEN. In
addition, MiNEN has an aggressive biological behaviour, usually driven by a poorly
differentiated neuroendocrine component. In nearly all cases, the non-neuroendocrine
component is of ADC histology. These findings are in line with those from other
retrospective  cohorts  of  MiNENs  where  the  neuroendocrine  component  was
predominant  in  50%-66.7%  of  tumour  samples  analysed [15 ,20-23]  and  poorly
differentiated  in  59%-100%  of  tumour  samples  analysed[12,15,19-26],  and  the  non-
neuroendocrine  component  was  of  ADC  or  adenoma  histology  in  66.7-100%  of
tumour  samples  analysed[10,15,20-27].  In  addition,  in  the  present  study,  the  NEC
component of MiNEN was predominantly of large cell morphology. Although this
information was available only for a small proportion of cases (16; 23%), two other
studies reported similar findings; a large cell NEC component in 41/42 and 10/10
MiNEN samples, respectively[20,24].
Interestingly, the present study suggests that, in MiNEN, the metastatic process is
dominated  by  a  single  component,  which  is  usually  of  NEC  histology.  This  is
corroborated by similar findings from an Italian and two Asian studies reporting on
patients with GEP MiNENs[15,20,23], and carries an important implication; biopsies of
metastatic sites may not capture both the tumour components, deceptively leading to
a diagnosis of pure NEC or ADC, especially in Adv cases when surgical material for
full sampling of the primary tumour is not available. This may also explain why the
majority of cases, in the present cohort of MiNENs, were diagnosed at a Loc stage,
which is unexpected for an aggressive disease; a proportion of Adv MiNENs may be
misdiagnosed due to limitations of tissue biopsies.
Consistent with other studies from the literature[8,11,19,20,22], curative surgery was the
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Figure 2
Figure 2  Kaplan-Meier curves for recurrence-free survival and overall survival in the localised stage subgroup, and for progression free survival and
overall survival in the advanced stage subgroup. The confidence interval gets wider with time mainly due to smaller sample sizes. The wider confidence intervals
indicate more uncertainty. MiNEN: Mixed neuroendocrine non-neuroendocrine neoplasm; med: Median; 95%CI: 95% confidence interval.
preferred  treatment  for  Loc  MiNEN,  and  pre-operative  and/or  post-operative
treatment  was  delivered to  between a  half  and three  quarters  of  resected cases.
Chemotherapy  and chemo-radiotherapy  regimens  in  the  Loc  setting  were  most
commonly adherent to the clinical practice guidelines for pure ADCs from the same
sites of origin; this might be explained by the lack of solid evidence advocating the
use of peri-operative chemotherapy or chemo-radiotherapy for potentially curable
pure neuroendocrine neoplasms.
In the present study, palliative chemotherapy was the most common treatment
offered to patients with Adv disease, whereas in the majority of reported studies on
MiNEN from the literature, surgery, either alone or in combination with palliative
chemotherapy, is the preferred management for this subgroup of patients[8,20-22,26,28,29].
This discrepancy might be explained by a selection bias, since most of those studies
were conducted in surgical cohorts, only including cases of MiNEN diagnosed by
surgical excision[8,20-22].
There is variability within the literature with regard to chemotherapy and chemo-
radiotherapy regimens (ADC-like or NEC-like) used in the palliative setting[8,19,20,22,29],
and the criteria driving the choice of the regimen remains unexplained. Similar to the
study  by  Apostolidis  et  al[19],  in  the  present  series,  first-line  chemotherapy  and
chemoradiotherapy regimens were in line with ADC-like or NEC-like protocols in
equal proportion. In addition, the choice of the regimen seemed to be based on the
predominant or most aggressive histology. Noticeably, in a proportion of cases, ADC-
l ike  plat inum-based  regimens  (e .g . ,  5 - f luorouraci l/oxal iplat in  or  5-
fluorouracil/irinotecan) were preferred, despite a predominant or more aggressive
neuroendocrine component; a possible explanation is that clinicians opted for such
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Table 3  Univariate analyses for recurrence-free-survival and overall survival in patients with a diagnosis of localised mixed
neuroendocrine non-neuroendocrine neoplasm
RFS OS
n Median (mo) 95%CI P value n Median (mo) 95%CI P value
Primary tumour site
Lower GI 25 15.70 10.1-NR 0.28 25 29.6 19.1-NR < 0.001
PB 4 8.11 2.9-NR 4 8.6 7.6-NR
Upper GI 5 14.89 8.0-NR 5 20.4 9.4-NR
Unknown 0 0
Age at diagnosis
< 70 yr 22 15.5 11.5-NR 0.023 22 32.6 20.7-NR 0.017
≥ 70 yr 12 9.2 6.5-NR 12 16.1 8.6-NR
ECOG PS
0-1 27 12.7 9.2-NR 0.29 27 29.6 18.3-NR 0.34
≥ 2 5 18.5 5.7-NR 5 28.6 14.3-NR
Gender
Female 14 7.0 4.2-NR 0.081 14 11.9 8.6-NR 0.037
Male 20 15.5 11.5-NR 20 32.6 19.1-NR
Predominant component
ADC 9 11.5 6.4-NR 0.99 9 20.7 15.9-NR 0.66
EQUAL 2 8.1 - 2 - -
NE 14 12.7 7.0-NR 14 20.4 18.3-NR
Grading NE component
G1 2 - - 0.16 2 - - 0.24
G2 2 33.7 24.4-NR 2 36.7 29.6-NR
G3 29 11.5 8.0-18.5 29 20.7 15.9-NR
Ki-67 of NE component
< 55% 9 17.1 2.9-NR 0.67 9 28.6 8.6-NR 0.83
≥ 55% 17 9.2 7.0-NR 17 19.1 14.3-NR
pN+
No 4 - - 0.015 4 - - 0.069
Yes 16 10.1 6.5 16 28.6 14.3-NR
Periop-treatment
No 13 14.0 7.0-NR 0.375 13 28.6 16.1-NR 0.24
Yes 19 14.9 8.0-NR 19 20.4 14.3-NR
RFS: Recurrent free survival; OS: Overall survival; 95%CI: 95% confidence interval; NR: Not reached; Lower GI: Lower gastrointestinal tract; Upper GI:
Upper gastrointestinal tract; PB: Pancreatico-biliary tract; PS: Performance status; ECOG: Eastern Cooperative Oncology Group; ADC: Adenocarcinoma;
EQUAL: Equal proportions of the two histologies; NE: Neuroendocrine component; pN+: Presence of metastatic loco-regional lymph nodes on post-
operative pathological examination; Periop: Perioperative (adjuvant and/or neoadjuvant chemotherapy and/or radiotherapy) .
combinations, which have shown anti-tumour activity in small retrospective series of
NECs[30,31], in an attempt to target both the components.
The results of the present study indicate that MiNEN has a poor prognosis, with a
high likelihood of recurrence or progression after a short period of time from the
initial management. Survival outcomes of MiNEN were close to those of pure GEP-
NECs[32-34],  and such a similarity was more evident in the Adv setting.  Similarly,
disease control rates to first-line palliative chemotherapy, which were consistent with
those from other series of MiNENs (60%-68%)[19,20], were close to those of pure GEP-
NECs (64%-100%)[32-34].
The present study summarises real-world data on an under-researched diagnosis,
providing suggestions for clinical practice (Figure 3). However, there are limitations
which are worth acknowledging. Firstly, it is a retrospective study and, therefore, the
data reported may not be as accurate as in prospective clinical trials; information on a
number of key pathological features (e.g., predominant component, histology of non-
neuroendocrine  component,  morphological  subtype  and  Ki-67  value  of  the
neuroendocrine component, and immunohistochemical data) could not be retrieved
from  medical  records  or  pathological  reports  in  non-negligible  proportions  of
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Table 4  Univariate analysis of progression-free survival and overall survival in patients with advanced mixed neuroendocrine non-
neuroendocrine neoplasm
PFS OS
n Median (mo) 95%CI P value n Median (mo) 95%CI P value
Primary tumour site
Lower GI 35 6.6 4.6-7.4 0.008 37 9.6 5.21-15.2 < 0.001
PB 7 4.4 0.8-NR 7 4.4 2-NR
Upper GI 11 9.5 5.1-NR 11 9.5 5.1-NR
Unknown 1 1.3 - 1 1.3 -
Age at diagnosis
< 70 yr 32 5.9 4.3-9.5 0.19 32 9.5 5.2-16.3 0.23
≥ 70 yr 22 5.6 3.8-8.0 22 9.0 4.6-14.7
ECOG PS
0-1 36 6.9 4.6-8.2 0.9 36 9.6 5.216.3 0.45
≥ 2 13 5.9 3.4-NR 13 5.9 4.6-NR
Gender
Female 20 5.2 2.6-9.1 0.5 20 7.9 3.7-19.8 0.96
Male 34 6.9 4.6-9.5 34 9.0 5.2-15.2
Predominant component
ADC 11 4.4 2.6-NR 0.08 11 4.4 2.6-NR 0.14
EQUAL 6 9.5 4.4-NR 6 34.2 12.4-NR
NE 23 5.6 4.3-7.2 23 7.2 5.2-13.7
Grading NE component
G1 0 0
G2 5 6.9 5.2-NR 0.65 5 53.8 5.2-NR 0.34
G3 49 5.6 4.4-7.4 49 9.0 5.2-13.4
Ki-67 of NE component
< 55% 14 7.0 5.3-12.9 0.78 10.7 5.6-NR 0.6
≥ 55% 32 4.7 3.9-8.0 7.2 5.15-13.4
First line active treatment
No 13 2.2 1.6 < 0.001 3.7 2.0 < 0.001
Yes 40 7.1 5.2-9.8 13.4 9.0-16.3
PFS: progression free survival; OS: overall survival; 95%CI: 95% confidence interval; NR: Not reached; Lower GI: Lower gastrointestinal tract; Upper GI:
Upper gastrointestinal tract; PB: Pancreatico-biliary tract; PS: Performance status; ECOG: Eastern Cooperative Oncology Group; ADC: Adenocarcinoma;
EQUAL: Equal proportions of  the two histologies;  NE: Neuroendocrine component;  Note:  Advanced mixed neuroendocrine non-neuroendocrine
neoplasms include both patients who presented with advanced disease at diagnosis and those who developed advanced recurrent disease after initial
curative treatment. First line active treatment includes palliative surgery alone, palliative surgery combined with chemotherapy, chemotherapy alone,
chemo-radiotherapy.
patients, and further pathological review of the samples was not feasible. Although it
would be interesting from a scientific standpoint to obtain the Ki-67 value and the
morphological subtype (small cell vs large cell) of the neuroendocrine component
from a larger number of patients, neither are proven prognostic or predictive factors
in this  disease subgroup and,  therefore,  currently,  this  information is  of  limited
relevance for clinical practice. Secondly, the results of univariate and multivariable
analyses have to be interpreted with caution, as the small sample size of comparator
subgroups would not permit reliable deductions. Furthermore, survival outcomes of
the  Adv subgroup might  be  biased by  the  inclusion  of  patients  who developed
metastatic recurrent disease after initial curative treatment for Loc MiNENs; some of
those  patients  who  had  received  previous  perioperative  treatment,  might  have
developed more chemo- and/or radiotherapy-resistant phenotypes, that might have
negatively influenced the outcomes of the whole Adv subgroup. Lastly, there may be
inaccuracies in diagnosis for those patients (around a third) having biopsy samples as
the only diagnostic material, since verifying the 30% threshold for each component
based on a limited amount of tissue might be challenging. However, biopsy samples
were reviewed by expert  pathologists,  who based their  conclusion on either  the
presence of an admixture of equal proportions of the two components within the
tumour  sample,  or  the  evidence  of  mixed exocrine/neuroendocrine  features  on
WJG https://www.wjgnet.com October 21, 2019 Volume 25 Issue 39
Frizziero M et al. MiNEN: A 5-centre retrospective study
6001
further tumour samples from the same patient.
To conclude,  due to limitations in diagnostic  methods (insufficient  amount of
tumour  tissue  provided  by  biopsies)  and  criteria  (a  quantitative  arbitrary  30%
threshold  for  each  component),  the  actual  incidence  of  MiNEN  may  be
underestimated  in  general  clinical  practice.  To  pursue  an  accurate  diagnosis  of
MiNEN, and therefore deliver the most appropriate management, in the presence of a
tumour from the GEP tract exhibiting a mixed histology and/or an unconventional
behaviour  on  standard  treatment,  the  tumour  sample  should  be  reviewed  by
pathologists with expertise in neuroendocrine neoplasms. Collection of additional
tumour material  from metastatic  sites is  also advisable to optimise the choice of
treatment.
Recent molecular and genetic studies on MiNEN have uncovered shared molecular
vulnerabil i t ies  between  the  neuroendocrine  and  non-neuroendocrine
components[24,25,35], suggesting a potential role for targeted treatments against both the
components, overcoming the long-standing problem of their differential sensitivity to
conventional chemotherapy and chemo-radiotherapy. Sample biobanking and wider
molecular analyses are paramount to forward the biological understanding of this
rare disease, to inform novel drug development treatments and patient allocation to
early-phase biomarker driven clinical trials. Liquid biopsies may aid in overcoming
the limitations of tissue biopsies.
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Figure 3
Figure 3  Algorithm of suggestions for clinical management of patients with a diagnosis of mixed neuroendocrine non-neuroendocrine neoplasm. NEC:
Neuroendocrine carcinoma; GEP: Gastro-entero-pancreatic tract; WHO: World Health Organisation.
ARTICLE HIGHLIGHTS
Research background
Mixed  neuroendocrine  non-neuroendocrine  neoplasm  (MiNEN)  is  characterised  by  the
coexistence of two histologies and is a rare disease, most commonly originating in the digestive
system. Evidence from the literature is limited and inconsistent.
Research motivation
Although rare, when encountered, MiNEN represents a therapeutic riddle for clinicians, as there
is still uncertainty as to how patients with this diagnosis should be managed, in the absence of
data  from  clinical  trials.  In  addition,  the  actual  incidence  of  MiNEN  remains  unknown.
Therefore, data from large retrospective studies is warranted.
Research objectives
The present study was designed to provide insights on the epidemiology and prognosis of
MiNEN  from  the  gastro-entero-pancreatic  tract  (GEP),  as  well  as  on  commonly  applied
therapeutic approaches, with the ultimate aim of providing some guidance for clinical practice.
Research methods
To this end, a large retrospective, multicentre collection of clinical-pathological and survival
data, and treatment modalities from patients with a diagnosis of GEP-MiNEN was carried out.
Original diagnostic samples were reviewed by pathologists with expertise in neuroendocrine
neoplasms to ascertain compliance with the most recent diagnostic criteria for MiNEN (WHO
classification 2017). Potential differences in survival outcomes between subgroups with distinct
clinical-pathological characteristics were also investigated.
WJG https://www.wjgnet.com October 21, 2019 Volume 25 Issue 39
Frizziero M et al. MiNEN: A 5-centre retrospective study
6003
Research results
MiNEN is most commonly diagnosed in the colon-rectum and oesophagus/oesophago-gastric
junction. The neuroendocrine component is almost always grade 3, and is most commonly the
predominant  histology in  both the  primary tumour and distant  metastatic  sites.  The non-
neuroendocrine  component  is  of  adenocarcinoma  histology  in  most  cases.  Patients  with
potentially curable MiNEN usually receive curative surgery, in combination or not with pre-
and/or post-operative chemotherapy and/or radiotherapy as per standard of care for pure
adenocarcinomas form the same sites of origin. Patients with advanced MiNEN most commonly
receive  chemotherapy  following  protocols  for  pure  neuroendocrine  carcinomas  or
adenocarcinomas from the same sites of origin. The prognosis of MiNEN is poor; patients with
initially curative MiNEN have a high likelihood of recurrence (around 2/3 of cases), with half of
cases developing disease recurrence within the first 12 months from curative treatment. Patients
with advanced stage MiNEN progress soon after the beginning of palliative treatment and have
survival outcomes very close to those of pure GEP-NECs.
Research conclusions
The incidence of MiNEN is likely underestimated, as tissue biopsies may not be able to capture
both the histologies; it is a predominantly metastatic disease, and metastatic sites are usually
occupied by a single component (most frequently G3, neuroendocrine). A pathological review of
the  samples  by  pathologists  with  expertise  in  neuroendocrine  neoplasms  is  strongly
recommended.  A  second  biopsy  from  metastatic  sites  is  encouraged,  whenever  possible,
especially  on  disease  progression.  Systemic  treatments  directed  against  one  of  the  two
components have limited efficacy. Novel drug development should exploit common biological
vulnerabilities between the two components. Biological studies and liquid biopsies may aid in
unveiling the molecular landscape of MiNEN, and informing drug development and clinical trial
design.
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